This report on the global angina pectoris treatment market studies various drugs used for treating angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischemia, which usually occurs with physical activity or emotional stress; in the United States, 10.2 million are estimated to experience angina, with approximately 500,000 new cases occurring each year. Thus, the drug pipeline of the angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.
For this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long – acting nitroglycerines, angiotensin-converting enzyme inhibitors, and anti-ischemic agents. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for 2016 to 2022, considering 2015 as the base year.
The pipeline analysis for the angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCID (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co., Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). In addition, the report also covers qualitative information associated with the drugs under phases II and I of the clinical trials.
The geographic segmentation of the global angina pectoris market is performed for the regions of North America, Europe, Asia Pacific, and the Rest of the World markets. The regions are also further sub-segmented based on major countries. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for 2016 to 2022, considering 2015 as the base year.
Drug Class Segmentation Analysis
Angina pectoris is temporary chest pain or discomfort resulting from decreased blood flow to the heart muscle, which is not a heart attack but a sign of increased risk. According to The British Journal of Cardiology, chronic stable angina pectoris affects around 2 – 4% of the population in western countries. It is associated with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1–2% and 3%, respectively.
Based on the drug class, the angina pectoris treatment market is segmented into:
Antiplatelet agents
Beta-adrenergic blocking agents
Calcium channel blockers
Short & Long-acting Nitroglycerines
Angiotensin-converting enzyme (ACE) inhibitors
Anti-ischemic agents
Beta-adrenergic blocking agents are the first-line drug for angina pectoris treatment. Beta-adrenergic blocking agents are one of the major drug classes in the angina pectoris treatment market. These agents improve the oxygen supply and demand balance by reducing heart rate and blood pressure, decreasing end-systolic stress and contractility, and prolonging diastole, allowing more coronary flow. The major factors assisting its growth are efficiency, fast onset of action, accessibility to patients, and high patient compliance.
Geography Segmentation Analysis
For this study, the global angina pectoris market is categorized into:
North America
Europe
Asia Pacific
Rest of the World
North America was observed as the largest market for angina pectoris treatment in the base year 2015. According to the American College of Cardiology, chronic angina pectoris affects over seven million North Americans annually. Despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic of coronary artery disease (CAD). The rising prevalence of angina pectoris, obesity in the young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris are major factors assisting the growth of the North American angina pectoris treatment market. Europe is the second largest market, followed by the Asia Pacific; considering the prevalence rate, Europe surpasses the Asia Pacific, and it’s considered the most attractive region in the angina pectoris therapeutics industry. However, Asia Pacific is estimated to pace at an exceptional growth rate due to the rising prevalence of angina pectoris, high awareness related to cardiovascular diseases, and developing healthcare infrastructure.
Frequently Asked Questions:
The market for Angina Pectoris Treatment is expected to reach US$ 12,589.6 Mn By 2022.
The Angina Pectoris Treatment market is expected to see significant CAGR growth over the coming years, at 5.2%.
The report is forecasted from 2015 to 2022.
The base year of this report is 2014.
Abbott Laboratories Inc., Business Description, Financial Health and Budget Allocation, Product Portfolio, News Coverage, Astra Zeneca plc, Business Description are some of the major players in the global market.
